Nitto Denko Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nitto Denko Corporation
Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies
Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.
Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
J&J Innovation’s Latest Deal Spree Includes CB-1 Antibody For NASH
Option to acquire a company developing a CB1-targeted antibody for non-alcoholic steatohepatitis gets Johnson & Johnson into the race. Janssen’s James List explains how the NASH venture fits into J&J’s growing efforts in metabolic disease.
Deals Shaping the Medical Industry, December 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Altea Therapeutics Corporation
- Avecia Biotechnology, Inc.
- Nitto BioPharma, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.